Point Of Care Diagnostic Testing World Markets

Point Of Care Diagnostic Testing World Markets

  1. 1. Overview 13
  2. 1.1 About this Report 13
  3. 1.2 Scope of the Report 14
  4. 1.3 Objectives 15
  5. 1.4 Methodology 15
  6. 1.5 Executive Summary 16
  7. 2. Overview of Diagnostic Testing Point of Care 20
  8. 2.1 Point of Care Testing Sites 20
  9. 2.2 Point of Care Market Structure 21
  10. 3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors 24
  11. 3.1 Global POCT Market 30
  12. 3.2 U.S. POCT Market 32
  13. 3.3 European POCT Market 34
  14. 3.3.1 German POCT Diagnostic Market 40
  15. 3.3.2 U.K. POCT Diagnostic Market 43
  16. 3.3.2.1 U.K. POCT Market Statistics 43
  17. 3.3.2.2 U.K. Competitive Analysis 45
  18. 3.3.2.3 U.K. Market Access 46
  19. 3.3.3 French POCT Diagnostic Market 46
  20. 3.3.4 Italian POCT Diagnostic Market 47
  21. 3.3.5 Spanish POCT Diagnostic Market 48
  22. 3.3.6 Scandinavian POCT Diagnostic Market 50
  23. 3.3.7 Swedish POCT Diagnostic Market 50
  24. 3.3.8 Finland POCT Diagnostic Market 51
  25. 3.3.9 Norway POCT Diagnostic Market 52
  26. 3.3.10 Swiss POCT Diagnostic Market 53
  27. 3.3.11 Dutch POCT Diagnostic Market 54
  28. 3.3.12 Belgian POCT Diagnostic Market 55
  29. 3.3.13 Portugal POCT Diagnostic Market 56
  30. 3.3.14 Austria POCT Diagnostic Market 57
  31. 3.3.15 Greek POCT Diagnostic Market 58
  32. 3.3.16 Poland POCT Diagnostic Market 59
  33. 3.3.17 Czech Republic POCT Diagnostic Market 60
  34. 3.3.18 Turkish POCT Diagnostic Market 61
  35. 3.4 Asian POCT Markets 62
  36. 3.4.1 Japanese POCT Diagnostic Market 62
  37. 3.4.2 Indian POCT Diagnostic Market 63
  38. 3.4.3 Chinese POCT Diagnostic Market 69
  39. 3.5 Rest of the World POCT Market 78
  40. 3.5.1 Canada POCT Diagnostic Market 78
  41. 3.5.2 Brazil POCT Diagnostic Market 79
  42. 3.5.3 Australia POCT Diagnostic Market 79
  43. 3.6 Overview of Asian Healthcare Market 80
  44. 3.6.1 Singapore 81
  45. 3.6.2 Malaysia 82
  46. 3.6.3 Thailand 82
  47. 3.6.4 Indonesia 83
  48. 3.6.5 Philippines 83
  49. 3.6.6 South Korea 83
  50. 3.6.7 Taiwan 84
  51. 4. POCT Individual Markets 85
  52. 4.1 Glucose Testing 85
  53. 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors 87
  54. 4.2.1 World Market 87
  55. 4.2.2 U.S. Market 87
  56. 4.2.3 European Market 89
  57. 4.2.4 Alternate Glucose Monitoring Products 90
  58. 4.2.5 HbA1c POCT 90
  59. 4.3 Blood Gas and Electrolytes 91
  60. 4.3.1 Whole Blood Lactate 94
  61. 4.4 Rapid Coagulation Tests 94
  62. 4.4.1 World POCT Coagulation Market 97
  63. 4.4.2 U.S. Coagulation Market 97
  64. 4.4.3 European Coagulation Market 100
  65. 4.4.4 Trends in POCT Coagulation Testing 100
  66. 4.5 Rapid Cardiac Markers 101
  67. 4.5.1 U.S. Market 101
  68. 4.5.2 European Market 103
  69. 4.6 Drugs of Abuse Screening Testing 104
  70. 4.6.1 Acetaminophen 111
  71. 4.6.2 Tricyclic Antidepressants (TCAs) 111
  72. 4.6.3 Other Toxic Drugs 112
  73. 4.6.4 Drug Testing Selectivity 112
  74. 4.6.5 Methaqualone and Phencyclidine (PCP) 112
  75. 4.6.6 Tetrahydrocannabinol 112
  76. 4.6.7 Drug Panels by Toxidromes 112
  77. 4.6.8 Alcohol Testing 113
  78. 4.7 Urine Strips 113
  79. 4.8 Pregnancy Tests 116
  80. 4.9 Fecal Occult Blood 118
  81. 4.10 Hemoglobin Testing 119
  82. 4.11 Miscellaneous Rapid Tests 119
  83. 4.11.1 Estriol 119
  84. 4.11.2 Fetal Fibronectin (fFN) 120
  85. 4.11.3 H. pylori 120
  86. 4.11.4 Vaginal pH and Vaginitis 120
  87. 4.11.5 Bladder Cancer 121
  88. 4.11.6 Fetal Status 122
  89. 4.11.7 Heparin-Induced Thrombocytopenia 123
  90. 4.12 Human Immunodeficiency Virus (HIV) 123
  91. 4.13 Cholesterol 129
  92. 4.14 Infectious Disease 130
  93. 4.14.1 C. difficile 130
  94. 4.14.2 Giardia 131
  95. 4.14.3 Salmonella and Campylobacter 132
  96. 4.14.4 Malaria Testing 132
  97. 4.14.5 Influenza Testing 134
  98. 4.14.6 Strep Testing 135
  99. 4.14.7 Chlamydia 137
  100. 4.14.8 Mononucleosis 138
  101. 4.14.9 Rubella 138
  102. 4.14.10 Methicillin-Resistant Staphylococcus Aureus (MRSA) 138
  103. 4.14.11 Hepatitis 145
  104. 4.14.12 Gonorrhea 147
  105. 4.14.13 Tuberculosis (TB) 148
  106. 4.14.14 Herpes Simplex Virus Type-2 150
  107. 4.15 Infant Jaundice 150
  108. 4.16 Anthrax 150
  109. 4.17 Rupture of Fetal Membranes (ROM) 152
  110. 4.18 Food Pathogens 152
  111. 4.19 Typhoid 152
  112. 5. POCT: Reagents and Equipment 153
  113. 5.1 Blood Glucose Monitoring 153
  114. 5.1.1 LifeScan 154
  115. 5.1.2 Roche Accu-Chek 157
  116. 5.1.3 Siemens Healthcare Diagnostics 157
  117. 5.1.4 Cholestech (Acquired by Inverness Medical Innovations) 159
  118. 5.1.5 Abbott Diabetes Care 159
  119. 5.1.6 International Technidyne Corporation 160
  120. 5.1.7 HemoCue 161
  121. 5.1.8 Stanbio/GDS Technology 161
  122. 5.1.9 Disetronic Medical Systems 162
  123. 5.1.10 Medtronic MiniMed 162
  124. 5.1.11 Abaxis 163
  125. 5.2 Blood Gas and Electrolytes 166
  126. 5.2.1 Roche Corporation 166
  127. 5.2.2 TechnoMedica 167
  128. 5.2.3 Siemens Healthcare Diagnostics 167
  129. 5.2.4 Instrumentation Laboratory 167
  130. 5.2.5 Nova Biomedical 167
  131. 5.2.6 Radiometer 168
  132. 5.2.7 Abbott Laboratories 168
  133. 5.2.8 Span Diagnostics 168
  134. 5.2.9 Avox Systems 168
  135. 5.2.10 ITC 170
  136. 5.2.11 OPTImedical 170
  137. 5.3 Rapid Coagulation Tests 170
  138. 5.3.1 POC Coagulation Instrument Description 175
  139. 5.3.1.1 Roche Diagnostics Corp. 175
  140. 5.3.1.2 Abbott Laboratories 177
  141. 5.3.1.3 International Technidyne Corp. 177
  142. 5.3.1.4 Medtronic 178
  143. 5.3.1.5 HemoSense (Inverness) 179
  144. 5.3.1.6 Helena Laboratories Point of Care 179
  145. 5.3.1.7 Sienco, Inc. 180
  146. 5.3.1.8 Accumetrics 181
  147. 5.3.2 Connectivity Issues 181
  148. 5.3.3 Cost Benefits 181
  149. 5.3.4 Quality Control Issues 182
  150. 5.3.5 Certification for POC Coagulation Devices 182
  151. 5.4 Rapid Cardiac Markers 183
  152. 5.4.1 Nanogen 183
  153. 5.4.2 Biosite Diagnostics (Inverness) 183
  154. 5.4.3 Roche Diagnostics 184
  155. 5.4.4 Ani Biotech 185
  156. 5.4.5 Response Biomedical Corporation 185
  157. 5.4.6 Siemens Healthcare Diagnostics 186
  158. 5.4.7 Lab21 Limited 187
  159. 5.4.8 Abbott Laboratories 187
  160. 5.4.9 LifeSign (Princeton BioMediTech Corp) 187
  161. 5.4.10 Mitsubishi Kagaku Iatron 187
  162. 5.5 Rapid Drugs of Abuse 187
  163. 5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations) 189
  164. 5.5.2 Abbott Diagnostics 190
  165. 5.5.3 Roche Diagnostics 190
  166. 5.5.4 BioScan Screening Systems, Inc. 191
  167. 5.5.5 American Bio Medica Corp. 192
  168. 5.5.6 Phamatech, Inc. 195
  169. 5.5.7 Worldwide Medical 196
  170. 5.5.8 OraSure 196
  171. 5.5.9 LifePoint 196
  172. 5.5.10 Avitar, Inc. 197
  173. 5.5.11 Cozart Biosciences 197
  174. 5.5.12 Pathtech 198
  175. 5.5.13 Alfa Scientific Designs, Inc. 198
  176. 5.5.14 TCPI, Inc. 198
  177. 5.5.15 Roche 199
  178. 5.5.16 Siemens Corporation 199
  179. 5.5.17 Diagnostic Chemical, Ltd. 200
  180. 5.5.18 Quidel 200
  181. 5.5.19 HemoCue (Quest) 200
  182. 5.6 Rapid Pregnancy and Fertility Tests 200
  183. 5.7 Fecal Occult Blood 202
  184. 5.7.1 Helena Laboratories 203
  185. 5.7.2 Biomerica 203
  186. 5.7.3 Beckman Coulter 203
  187. 5.7.4 Worldwide Medical 203
  188. 5.7.5 Aerscher Diagnostics 203
  189. 5.7.6 Enterix 204
  190. 5.7.7 Medix Biochemica 204
  191. 5.8 Hemoglobin Testing 204
  192. 5.8.1 Wampole Laboratories 204
  193. 5.8.2 HemoCue, Inc. 204
  194. 5.8.3 Stanbio/GDS Technology 205
  195. 5.9 Miscellaneous Rapid Tests 205
  196. 5.9.1 Triage C. difficile Panel 205
  197. 5.9.2 Ketoacids 205
  198. 5.9.3 Acetaminophen 205
  199. 5.9.4 Estriol 206
  200. 5.9.5 H. pylori 206
  201. 5.9.6 Vaginal Fluid pH and Vaginitis 208
  202. 5.9.7 Prostate Specific Antigen (PSA) 209
  203. 5.9.8 Bladder Cancer 209
  204. 5.9.9 Other Rapid Cancer Tests 212
  205. 5.9.10 Fetal Status (PROM) 213
  206. 5.9.11 Osteoporosis 213
  207. 5.9.12 Hemodynamic Monitoring 213
  208. 5.9.13 Heparin-Induced Thrombocytopenia 214
  209. 5.10 HIV 214
  210. 5.10.1 Whole Blood, Serum or Plasma-Based HIV Tests 216
  211. 5.10.1.1 Bio-Rad Laboratories 216
  212. 5.10.1.2 Orgenics (wholly-owned by Inverness Medical Innovations) 216
  213. 5.10.1.3 StatSure Diagnostic Systems 217
  214. 5.10.1.4 Trinity Biotech 217
  215. 5.10.1.5 Savyon Diagnostics 217
  216. 5.10.1.6 MedPharm 217
  217. 5.10.1.7 American Bio Medica Corp. 217
  218. 5.10.1.8 Chembio Diagnostics 218
  219. 5.10.1.9 OraSure 218
  220. 5.10.1.10 Inverness 219
  221. 5.10.2 Saliva-Based HIV Tests 219
  222. 5.10.2.1 OraSure Collection Device 220
  223. 5.10.2.2 SureStat 221
  224. 5.10.3 Urine-Based HIV Tests 221
  225. 5.10.3.1 MedMira Laboratories, Inc. 221
  226. 5.10.3.2 Medical Services International, Inc. 222
  227. 5.10.3.3 Maxim Biomedical 222
  228. 5.10.3.4 Wampole Laboratories 222
  229. 5.11 Cholesterol 222
  230. 5.11.1 Cholestech (Now a Brand of Inverness Medical Innovations) 223
  231. 5.11.2 Actimed Laboratories 224
  232. 5.11.3 StatSite Meter 224
  233. 5.11.4 Polymer Technology Systems 225
  234. 5.11.5 PreMD Inc. (f/k/a International Medical Innovations, Inc. (IMI)) 225
  235. 5.11.6 Abaxis, Inc. 225
  236. 5.12 Infectious Disease 225
  237. 5.12.1 C. difficile 225
  238. 5.12.2 Giardia 226
  239. 5.12.3 Dengue Fever 227
  240. 5.12.4 Malaria Testing 227
  241. 5.12.5 Rapid Influenza Testing 229
  242. 5.12.6 Streptococcus Testing 229
  243. 5.12.7 Chlamydia 231
  244. 5.12.8 Mononucleosis 231
  245. 5.12.9 Rubella 233
  246. 5.12.10 Staphylococcus Aureus and MRSA 233
  247. 5.12.11 Hepatitis 234
  248. 5.12.12 E. Coli O157 236
  249. 5.12.13 Gonorrhea Testing 236
  250. 5.12.14 Smallpox 236
  251. 5.12.15 SARS 236
  252. 5.12.16 Rabies 236
  253. 5.12.17 Tuberculosis 237
  254. 5.12.18 Avian Flu 237
  255. 5.12.19 West Nile Virus 237
  256. 5.12.20 Herpes Simplex Virus Type-2 237
  257. 5.13 Infant Jaundice 238
  258. 5.14 Anthrax 238
  259. 5.15 Homeland Defense (Plague and Tularemia) 239
  260. 5.16 BSE (Mad Cow Disease) 239
  261. 5.17 Tuberculosis 240
  262. 5.18 Typhoid 240
  263. 5.19 Avian Flu 240
  264. 5.20 Food Pathogens (Salmonella, Listeria, Campylobacter) 241
  265. 5.21 Ruptured Fetal Membranes (ROM) 242
  266. 6. POCT: Growth Regulators 243
  267. 6.1 Moderators of Growth 243
  268. 6.2 Personnel Acceptance 243
  269. 6.3 Key People for POCT 244
  270. 6.4 Information Management Issues 244
  271. 6.4.1 Elements of Information Management for POCT: Information Processing Capabilities 245
  272. 6.4.2 Data Mining 246
  273. 6.4.3 Middleware 246
  274. 6.4.4 Web Portals 247
  275. 6.4.5 POCT-1A Standard 247
  276. 6.5 Key Elements for POCT 248
  277. 6.6 POCT and Reimbursement 248
  278. 6.7 Effectiveness of Clinical Outcomes 250
  279. 6.8 Rapid Near-Patient Testing in Hospitals 250
  280. 6.9 Satellite Facilities 251
  281. 6.10 Regionalization of Laboratory Care 252
  282. 6.11 Requirements for POCT 253
  283. 6.12 Locations of Point of Care for Patient Care 254
  284. 6.13 Benefits of POCT 254
  285. 6.14 Cost Elements of POCT 254
  286. 6.15 Necessary Functions in POCT 255
  287. 6.16 TAT for POCT 255
  288. 6.17 Clinical Laboratory Improvement Amendments (CLIA) 255
  289. 6.18 Sexually-Transmitted Diseases in Underdeveloped Countries 257
  290. 7. Business Trends in the Point of Care Sector 258
  291. 7.1 Sector Consolidation 258
  292. 7.2 Diagnostic Testing Growth Trends 258
  293. 7.3 Acquisition, License Agreements, Internal Development and Partnerships 259
  294. 7.4 Product Testing Depth in POCT 263
  295. 7.5 Government Regulation 263
  296. 7.5.1 U.S. Regulation 263
  297. 7.5.1.1 Importing Medical Devices into the U.S. 264
  298. 7.5.1.2 Exporting Medical Devices from the U.S. 265
  299. 7.5.2 U.K. Regulation 265
  300. 7.5.3 E.U. Regulation 267
  301. 7.5.3.1 French Regulation 268
  302. 7.5.4 Japanese Regulation 269
  303. 7.5.5 Korean Regulation 269
  304. 7.6 Increased Market Penetration 269
  305. 7.7 Costs of Doing Business in Europe 270
  306. 7.8 Drivers of European Diagnostics Testing 271
  307. 7.9 European Reimbursement Practices 271
  308. 7.10 Cost Containment in Europe 271
  309. 8. Technology Platform Innovations in POCT 272
  310. 8.1 Sensor Systems for Diagnostic Applications 272
  311. 8.2 Glucose Measurements 275
  312. 8.3 Glucose Test Methods 277
  313. 8.4 Cholesterol Testing 278
  314. 8.5 The New Paradigm 279
  315. 8.6 Consolidated Workstations and Modularity 279
  316. 8.7 Automation and Robotics in the Clinical Laboratory 279
  317. 8.8 Laboratory Information Systems (LIS) 280
  318. 8.8.1 NOVIUS Lab 280
  319. 8.9 Biosensor Technology 280
  320. 8.10 Nanogen Third Generation POC Analyzer 282
  321. 8.11 Quidel MChip 283
  322. 9. Data Management and Connectivity 284
  323. 9.1 Wireless LANs 284
  324. 9.2 Connectivity Platforms 286
  325. 9.2.1 DataLink Data Management System 287
  326. 9.2.2 RALS-Plus 288
  327. 9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite 289
  328. 9.2.2.2 Siemens Diagnostics Rapidpoint® Coag 290
  329. 9.2.2.3 Radiometer 290
  330. 9.2.2.4 HemoCue's DM Hemoglobin 290
  331. 9.2.2.5 Roche Diagnostics 290
  332. 9.2.3 BD.id 291
  333. 9.2.4 Medical Implant Communications Service (MICS) 291
  334. 9.3 Advantages of POCT Connectivity 291
  335. 9.3.1 Cost Benefit of POCT and IT Connectivity 291
  336. 9.3.2 Hospital Network Issues 292
  337. 10. Corporate Profiles 293
  338. 10.1 Abaxis, Inc. 293
  339. 10.2 Abbott Diagnostics 297
  340. 10.3 Accumetrics, Inc. 300
  341. 10.4 Accurex Biomedical, Pvt., Ltd. 301
  342. 10.5 Akers Biosciences 301
  343. 10.6 Alfa Scientific Design, Inc. 301
  344. 10.7 Ambri, Ltd. 301
  345. 10.8 American Bio Medica Corp. 302
  346. 10.9 Ani Biotech 303
  347. 10.10 Apogent Technologies 303
  348. 10.11 Ark Therapeutics 303
  349. 10.12 ARKRAY 304
  350. 10.13 Atlas Genetics 304
  351. 10.14 Atonomics 304
  352. 10.15 Avitar, Inc. 304
  353. 10.16 Avox Systems 305
  354. 10.17 Axis-Shield 305
  355. 10.18 Beckman Coulter 306
  356. 10.19 Binax Corporation 310
  357. 10.20 Biomerica 310
  358. 10.21 BioMérieux Vitek, Inc. 311
  359. 10.22 BioScan Screening Systems, Inc. 311
  360. 10.23 Biosite Diagnostics 311
  361. 10.24 BioStar 311
  362. 10.25 British Biocell Holdings 311
  363. 10.26 Caliper Life Sciences 312
  364. 10.27 Calypte Biomedical 313
  365. 10.28 Chembio Diagnostics 313
  366. 10.29 Cholestech 314
  367. 10.30 Chongqing Sungene Pharmaceutical Co., Ltd. 314
  368. 10.31 CompuCyte Corporation 315
  369. 10.32 Cortech Diagnostics Ltd. (Now Called Kent International Holdings) 315
  370. 10.33 Cozart Biosciences 315
  371. 10.34 Cygnus Therapeutic Systems 315
  372. 10.35 Cytogen 316
  373. 10.36 DexCom 316
  374. 10.37 Daiichi Sankyo Group 317
  375. 10.38 Denka Seiken Co., Ltd. 317
  376. 10.39 Diagnostic Chemicals, Ltd. 317
  377. 10.40 Enterix, Inc. 317
  378. 10.41 Focus Diagnostics, Inc. 317
  379. 10.42 GDS Technology 317
  380. 10.43 GenBio 318
  381. 10.44 Genzyme Diagnostics 318
  382. 10.45 Grant Life Sciences 320
  383. 10.46 Gryphus Diagnostics 320
  384. 10.47 Helena Laboratories 321
  385. 10.48 Hema Diagnostic Systems 321
  386. 10.49 Hemocue, Inc. 322
  387. 10.50 Home Access Health Corp. 322
  388. 10.51 Immunoscience, Inc. 322
  389. 10.52 Instrumentation Laboratory 322
  390. 10.53 International Medical Innovations 323
  391. 10.54 Inverness Medical Innovations 323
  392. 10.55 Johnson & Johnson 328
  393. 10.56 Kyowa Medex Co., Ltd. 330
  394. 10.57 LifeAssays 330
  395. 10.58 LifePoint, Inc. 330
  396. 10.59 LifeScan Corporation 330
  397. 10.60 Lifestream Technologies 331
  398. 10.61 LXN Corp. (Inverness Medical Technologies) 331
  399. 10.62 Matritech 331
  400. 10.63 Medical Services International, Inc. 331
  401. 10.64 MediSense 332
  402. 10.65 Medisys 332
  403. 10.66 Medix Biochemica 332
  404. 10.67 MedMira Laboratories 332
  405. 10.68 Meretek Corporation 334
  406. 10.69 Meridian Bioscience 334
  407. 10.70 MiniMed 336
  408. 10.71 Mitsubishi Chemical U.S.A, Inc. 336
  409. 10.72 Mitsubishi Kagaku Iatron 337
  410. 10.73 Nanogen 337
  411. 10.74 New Horizons Diagnostics 338
  412. 10.75 Nova Biomedical 338
  413. 10.76 OraSure 340
  414. 10.77 Orgenics 344
  415. 10.78 Orion Diagnostica 344
  416. 10.79 PanBio, Ltd. 344
  417. 10.80 Phamatech, Inc. 344
  418. 10.81 PharmaNetics, Inc. 345
  419. 10.82 Polymedco 345
  420. 10.83 Polymer Technology Systems 346
  421. 10.84 Princeton BioMeditech Corporation 346
  422. 10.85 Quest Diagnostics 346
  423. 10.86 Quidel 347
  424. 10.87 Radiometer 351
  425. 10.88 Response Biomedical Corp. 353
  426. 10.89 Roche Diagnostics 354
  427. 10.90 Royal Philips Electronics 355
  428. 10.91 Savyon Diagnostics 356
  429. 10.92 Selfcare, Inc. 357
  430. 10.93 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech) 357
  431. 10.94 Shionogi & Co., Ltd. 357
  432. 10.95 Siemens Corporation 357
  433. 10.96 SpectRx, Inc. 358
  434. 10.97 Spectral Diagnostics 359
  435. 10.98 StatSure Diagnostic Systems 359
  436. 10.99 Strategic Diagnostics 360
  437. 10.100 Sun Biomedical Laboratories 360
  438. 10.101 Thoratec/International Technidyne Corp. 360
  439. 10.102 Transmedica 362
  440. 10.103 Trinity Biotech 362
  441. 10.104 Vasamed, Inc. 364
  442. 10.105 Venkateshwara Hatcheries Pvt., Ltd. 365
  443. 11. POCT Sector Trends and Forecasts 366
  444. 11.1 Home Care Analysis as Part of Near-Patient Testing 366
  445. 11.2 Non-Traditional Collection for POCT 366
  446. 11.3 New Systems for Critical Care and Near-Patient Testing 366
  447. 11.4 Utility of Near-Patient Testing in Critical Care Settings 366
  448. 11.5 Physician's Office Market 367
  449. 11.6 Information Management Advances 367
  450. 11.7 Test-Ordering Patterns and Demand for POCT 368
  451. 11.8 Demand for Emergency Department Services 368
  452. 11.9 Move Away From Central Laboratory 369
  453. 11.10 Healthcare Cost Controls 370
  454. 11.11 M&A in POCT 370
  455. 11.12 Competition for Services 370
  456. 11.13 Drivers of POCT 371
  457. 11.14 Confluence of New Technology 371
  458. 11.15 Difficulties of Design for POC Products 371
  459. 11.16 European Hospital Structure 372
  460. 11.17 The Biggest New Opportunities in Point of Care Testing 372
  461. 12. Corporate Directory 373
  462. LIST OF TABLES
  463. Table 2.1: Percentage of Point of Care Testing Performed in Selected Hospitals 21
  464. Table 2.2: Point of Care Testing Procedural Advantages for Hospital Testing 23
  465. Table 2.3: Point of Care Testing Trends 23
  466. Table 2.4: Professional Point of Care Testing Compared to Home Testing 23
  467. Table 2.5: Drivers for Integrating Point of Care Testing into Hospital Routines 23
  468. Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008 24
  469. Table 3.2: Number of Point of Care Tests in U.S., 2000-2012 25
  470. Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010 27
  471. Table 3.4: Overall In Vitro Diagnostic Testing Market Worldwide, 2007 28
  472. Table 3.5: Worldwide Distribution of IVD Testing, 2008 28
  473. Table 3.6: Top Twelve Country IVD Testing Markets, 2007 29
  474. Table 3.7: Thirteen Largest Diagnostic Companies Worldwide, 2007